These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 19300538)

  • 1. Venlafaxine in the treatment of panic disorder.
    Katzman MA; Jacobs L
    Neuropsychiatr Dis Treat; 2007 Feb; 3(1):59-67. PubMed ID: 19300538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Venlafaxine in the treatment of anxiety disorders.
    Katzman M
    Expert Rev Neurother; 2004 May; 4(3):371-81. PubMed ID: 15853535
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of anxiety disorders with venlafaxine XR.
    Thase ME
    Expert Rev Neurother; 2006 Mar; 6(3):269-82. PubMed ID: 16533131
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serotonin and Norepinephrine Reuptake Inhibitors.
    Shelton RC
    Handb Exp Pharmacol; 2019; 250():145-180. PubMed ID: 30838456
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Moving from serotonin to serotonin-norepinephrine enhancement with increasing venlafaxine dose: clinical implications and strategies for a successful outcome in major depressive disorder.
    Fagiolini A; Cardoner N; Pirildar S; Ittsakul P; Ng B; Duailibi K; El Hindy N
    Expert Opin Pharmacother; 2023; 24(15):1715-1723. PubMed ID: 37501324
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Bupropion: a review of its use in the management of major depressive disorder.
    Dhillon S; Yang LP; Curran MP
    Drugs; 2008; 68(5):653-89. PubMed ID: 18370448
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term management of major depressive disorder: are differences among antidepressant treatments meaningful?
    Shelton CI
    J Clin Psychiatry; 2004; 65 Suppl 17():29-33. PubMed ID: 15600379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Agomelatine versus other antidepressive agents for major depression.
    Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs) for the prevention of tension-type headache in adults.
    Banzi R; Cusi C; Randazzo C; Sterzi R; Tedesco D; Moja L
    Cochrane Database Syst Rev; 2015 May; 2015(5):CD011681. PubMed ID: 25931277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Venlafaxine extended-release: a review of its use in the management of major depression.
    Wellington K; Perry CM
    CNS Drugs; 2001; 15(8):643-69. PubMed ID: 11524036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Achieving remission from depression with venlafaxine and venlafaxine extended release: a literature review of comparative studies with selective serotonin reuptake inhibitors.
    Rudolph RL
    Acta Psychiatr Scand Suppl; 2002; (415):24-30. PubMed ID: 12492770
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR in treating major depressive disorder in Scotland.
    Benedict A; Arellano J; De Cock E; Baird J
    J Affect Disord; 2010 Jan; 120(1-3):94-104. PubMed ID: 19497623
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacy and medical costs associated with switching between venlafaxine and SSRI antidepressant therapy for the treatment of major depressive disorder.
    Khandker RK; Kruzikas DT; McLaughlin TP
    J Manag Care Pharm; 2008 Jun; 14(5):426-41. PubMed ID: 18597572
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative efficacy between venlafaxine and SSRIs: a pooled analysis of patients with depression.
    Stahl SM; Entsuah R; Rudolph RL
    Biol Psychiatry; 2002 Dec; 52(12):1166-74. PubMed ID: 12488062
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.
    Foster RH; Goa KL
    CNS Drugs; 1997 Aug; 8(2):163-88. PubMed ID: 23338224
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacotherapy for social anxiety disorder (SAnD).
    Williams T; Hattingh CJ; Kariuki CM; Tromp SA; van Balkom AJ; Ipser JC; Stein DJ
    Cochrane Database Syst Rev; 2017 Oct; 10(10):CD001206. PubMed ID: 29048739
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Venlafaxine treatment of panic disorder: a case series.
    Geracioti TD
    J Clin Psychiatry; 1995 Sep; 56(9):408-10. PubMed ID: 7665539
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in Pharmacotherapy for Pediatric Anxiety Disorders.
    Nicotra CM; Strawn JR
    Child Adolesc Psychiatr Clin N Am; 2023 Jul; 32(3):573-587. PubMed ID: 37201968
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A multinational pharmacoeconomic evaluation of acute major depressive disorder (MDD): a comparison of cost-effectiveness between venlafaxine, SSRIs and TCAs.
    Doyle JJ; Casciano J; Arikian S; Tarride JE; Gonzalez MA; Casciano R
    Value Health; 2001; 4(1):16-31. PubMed ID: 11704969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of sertraline versus venlafaxine XR in major depression: efficacy and discontinuation symptoms.
    Sir A; D'Souza RF; Uguz S; George T; Vahip S; Hopwood M; Martin AJ; Lam W; Burt T
    J Clin Psychiatry; 2005 Oct; 66(10):1312-20. PubMed ID: 16259546
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.